Comments on .
作者信息
Jin Kemin, Xing Baocai
机构信息
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepatobiliary and Pancreatic Surgery Unit I, Peking University Cancer Hospital & Institute, Beijing 100142, China.
出版信息
Chin J Cancer Res. 2022 Dec 30;34(6):637-643. doi: 10.21147/j.issn.1000-9604.2022.06.13.
Abstract
摘要
相似文献
1
Comments on .关于……的评论
Chin J Cancer Res. 2022 Dec 30;34(6):637-643. doi: 10.21147/j.issn.1000-9604.2022.06.13.
2
Comments on .关于……的评论
Chin J Cancer Res. 2023 Oct 30;35(5):431-432. doi: 10.21147/j.issn.1000-9604.2023.05.01.
3
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):453-455. doi: 10.21147/j.issn.1000-9604.2022.05.04.
4
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):447-450. doi: 10.21147/j.issn.1000-9604.2022.05.02.
5
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):458-459. doi: 10.21147/j.issn.1000-9604.2022.05.06.
6
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):451-452. doi: 10.21147/j.issn.1000-9604.2022.05.03.
7
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):456-457. doi: 10.21147/j.issn.1000-9604.2022.05.05.
8
Corrigendum to Comments on .关于……的评论的勘误
Chin J Cancer Res. 2022 Dec 30;34(6):644. doi: 10.21147/j.issn.1000-9604.2022.06.14.
9
Comments on .关于……的评论
Chin J Cancer Res. 2022 Dec 30;34(6):635-636. doi: 10.21147/j.issn.1000-9604.2022.06.12.
10
Comments on .关于……的评论
Chin J Cancer Res. 2022 Dec 30;34(6):633-634. doi: 10.21147/j.issn.1000-9604.2022.06.11.
引用本文的文献
1
State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine.胰腺癌治疗的最新进展与未来创新：向精准医学迈进的一步
Cancers (Basel). 2023 Jun 30;15(13):3423. doi: 10.3390/cancers15133423.
本文引用的文献
1
Computed tomography-guided single celiac plexus neurolysis analgesic efficacy and safety: a systematic review and meta-analysis.计算机断层扫描引导下腹腔神经丛单次阻滞的镇痛效果和安全性：系统评价和荟萃分析。
Abdom Radiol (NY). 2022 Nov;47(11):3892-3906. doi: 10.1007/s00261-022-03670-7. Epub 2022 Sep 10.
2
National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version).《2022年中国胰腺癌诊疗指南》（英文版）
Chin J Cancer Res. 2022 Jun 30;34(3):238-255. doi: 10.21147/j.issn.1000-9604.2022.03.05.
3
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.POLO 试验的总生存结果：一项奥拉帕利与安慰剂用于胚系 BRCA 突变转移性胰腺癌维持治疗的 III 期研究。
J Clin Oncol. 2022 Dec 1;40(34):3929-3939. doi: 10.1200/JCO.21.01604. Epub 2022 Jul 14.
4
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.阿法替尼治疗存在 HER 家族基因异常的实体瘤患者的 2 期临床试验：MOBILITY3 篮子研究。
Target Oncol. 2022 May;17(3):271-281. doi: 10.1007/s11523-022-00884-z. Epub 2022 May 30.
5
Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies.在组织学研究中，ERBB2 作为预测胰腺癌患者生存的工具的意义。
Curr Oncol. 2022 Mar 30;29(4):2442-2453. doi: 10.3390/curroncol29040198.
6
Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter prospective trial.EUS 引导下腹腔神经丛松解术联合 EUS 引导下腹腔神经节松解术治疗胰腺癌相关性疼痛的疗效：一项多中心前瞻性试验。
Int J Clin Oncol. 2022 Jul;27(7):1196-1201. doi: 10.1007/s10147-022-02160-6. Epub 2022 Apr 12.
7
Celiac Plexus Neurolysis Is Associated With Decreased Survival in Patients With Pancreatic Cancer: A Propensity Score Analysis.腹腔神经丛松解术与胰腺癌患者生存率降低相关：倾向评分分析。
Pancreas. 2022 Feb 1;51(2):153-158. doi: 10.1097/MPA.0000000000001992.
8
Direct intraoperative versus percutaneous computed tomographyguided celiac plexus neurolysis in non-resectable pancreatic cancer: A randomized, controlled, non-inferiority study.直接术中与经皮 CT 引导腹腔神经丛松解术治疗不可切除胰腺癌的随机对照非劣效性研究。
Rev Esp Anestesiol Reanim (Engl Ed). 2022 Feb;69(2):71-78. doi: 10.1016/j.redare.2022.02.001. Epub 2022 Feb 17.
9
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).阿达格拉西布（MRTX849）在晚期实体瘤患者中的首次人体 I/IB 期剂量发现研究（KRYSTAL-1）。
J Clin Oncol. 2022 Aug 10;40(23):2530-2538. doi: 10.1200/JCO.21.02752. Epub 2022 Feb 15.
10
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.可切除和边缘可切除胰腺癌的新辅助放化疗与 upfront 手术比较：荷兰随机 PREOPANC 试验的长期结果。
J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27.
Zotero 插件